Continuation and long-term maintenance treatment with Hypericum extract WS® 5570 after recovery from an acute episode of moderate depression - A double-blind, randomized, placebo controlled long-term trial

European Neuropsychopharmacology

Volumn 18, Issue 11, 2008, Pages 803-813

  Kasper, S ^a   Volz, H P ^b   Moller H J ^c   Dienel, A ^d   Kieser, M ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Schloss Werneck   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic unipolar depression; Hypericum; Long term study; Placebo; Prophylactic treatment; Recurrence; Relapse

Indexed keywords

HYPERICUM EXTRACT; PLACEBO; UNCLASSIFIED DRUG; WS 5570;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; INFECTION; INFESTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTPATIENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; OUTPATIENTS; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SAMPLE SIZE; SERTRALINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 52949111480     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.06.006     Document Type: Article

References (38)

1. Beck A.T., and Steer R.A. Internal consistencies of the original and revised Beck Depression Inventory. J. Clin. Psychol. 40 (1984) 1365-1367
2. Ernst E., Rand J.I., Barnes J., and Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 54 (1998) 589-594
3. Fava G.A., Ruini C., and Sonino N. Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach. CNS Drugs 17 (2003) 1109-1117
4. Gastpar M., Singer A., and Zeller K. Efficacy and tolerability of Hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38 (2005) 78-86
5. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., and Goodwin G.M. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361 (2003) 653-661
6. Gould A.L. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Stat. Med. 11 (1992) 55-66
7. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6 (1967) 278-296
8. Kasper S. Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 34 Suppl 1 (2001) S51-55
9. Kasper S., and Kasper A. Langzeitbehandlung affektiver Störungen. Nervenarzt 65 (1994) 577-589
10. ® 5570 after successful acute treatment of mild to moderate depression-rationale and study design. Int. J. Methods Psychiatr. Res. 13 (2004) 176-183
11. Kasper S., Lehofer M., Anditsch M., Bach M., Butterfield-Meissl C., Conca A., Danzinger R., Deisenhammer E.A., Friedrich M.H., Geretsegger C., Haring C., Haushofer M., Hofmann P., Kalousek M., Kapfhammer H.P., Klier C., Lingg A., Marksteiner J., Meißel T., Miller H., Musalek M., Naderi-Heiden A., Platz T., Purtscher A.K., Rießland-Seifert A., Rittmannsberger H., Saletu B., Schubert H., Simhandl C., Stamenkovic M., Stuppäck C., Windhager E., Whitwort A., Wolf W., and Wrobel M. Depression - Medikamentöse Therapie. Konsensus-Statement - State of the Art 2007. CliniCum psy (2007) 1-24
12. Keller M.B. The long-term treatment of depression. J. Clin. Psychiatry 60 Suppl 17 (1999) 41-45 discussion 46-48
13. Keller M.B. Long-term treatment of recurrent and chronic depression. J. Clin. Psychiatry 62 Suppl 24 (2001) 3-5
14. Keller M.B. Rationale and options for the long-term treatment of depression. Hum. Psychopharmacol. 17 Suppl 1 (2002) S43-46
15. Keller M.B., and Boland R.J. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol. Psychiatry 44 (1998) 348-360
16. Kennedy N., Abbott R., and Paykel E.S. Remission and recurrence of depression in the maintenance era: long-term outcome in a Cambridge cohort. Psychol. Med. 33 (2003) 827-838
17. Kim H.L., Streltzer J., and Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. J. Nerv. Ment. Dis. 187 (1999) 532-538
18. Kupfer D.J. Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. J. Clin. Psychiatry 52 (1991) 12-16 Suppl, discussion 17
19. Kupfer D.J., Frank E., Perel J.M., Cornes C., Mallinger A.G., Thase M.E., McEachran A.B., and Grochocinski V.J. Five-year outcome for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 49 (1992) 769-773
20. Laakmann G., Schüle C., Baghai T., Dienel A., and Kieser M. Clinical significance of hyperforin for the efficacy of Hypericum extracts on depressive disorders of different severities. Phytomedicine 5 (1998) 435-442
21. Lépine J.P., Gastpar M., Mendlewicz J., and Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12 (1997) 19-29
22. Linde K., and Knüppel L. Large-scale observational studies of Hypericum extracts in patients with depressive disorders-a systematic review. Phytomedicine 12 (2005) 148-157
23. Linde K., Berner M., Egger M., and Mulrow C. St John's wort for depression: meta-analysis of randomised controlled trials. Br. J. Psychiatry 186 (2005) 99-107
24. Melfi C.A., Chawla A.J., Croghan T.W., Hanna M.P., Kennedy S., and Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch. Gen. Psychiatry 55 (1998) 1128-1132
25. Möller H.J. Methodological problems of long-term studies in psychopharmacology. Pharmacopsychiatry 19 (1986) 156-160
26. Montgomery S.A. The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. Eur. Neuropsychopharmacol. 9 (1999) 271-276
27. Montgomery S.A., and Kasper S. Depression: a long-term illness and its treatment. Int. Clin. Psychopharmacol. 13 Suppl 6 (1998) S23-26
28. Montgomery S.A., and Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int. Clin. Psychopharmacol. 22 (2007) 283-291
29. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy W., and Bonato R.R. (Eds). Manual for the EDCEU Assessment Battery. U.S. National Institute of Mental Health, Psychopharmacology Research Branch, Chevy Chase, Md. (1976) 1211-1216
30. Prien R.F., and Klett C.H. Lithium carbonate and imipramine in prevention of affective episodes. Arch. Gen. Psychiatry 29 (1973) 420-425
31. Prien R.F., and Kupfer D.J. Continuation drug therapy for major depressive episodes: how long should it be maintained?. Am. J. Psychiatry 143 (1986) 18-23
32. Raskin J., Goldstein D.J., Mallinckrodt C.H., and Ferguson M.B. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry 64 (2003) 1237-1244
33. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., Beasley Jr. C.M., Michelson D., Roback P., and Sundell K. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry 155 (1998) 1247-1253
34. Rychlik R., Siedentop H., von den Driesch V., and Kasper S. Johanniskrautextrakt WS 5572 bei leichten bis mittelschweren Depressionen. Wirksamkeit und Verträglichkeit von 600 und 1200 mg Wirkstoff täglich. Fortschr. Med. 119 (2001) 119-128
35. Simon J.S., Aguiar L.M., Kunz N.R., and Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J. Psychiatr. Res. 38 (2004) 249-257
36. Storosum J.G., van Zwieten B.J., Vermeulen H.D., Wohlfarth T., and van den Brink W. Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. Eur. Psychiatr. 16 (2001) 327-335
37. Trautmann-Sponsel R.D., and Dienel A. Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials. J. Affect. Disord. 82 (2004) 303-307
38. Wurglics M., Westerhoff K., Kaunzinger A., Wilke A., Baumeister A., Dressman J., and Schubert-Zsilavecz M. Comparison of German St. John's wort products according to hyperforin and total hypericin content. J. Am. Pharm. Assoc. (Wash) 41 (2001) 560-566